When Do You Recommend Molecular Profiling of Tumors?

Article

How often do you refer patients for molecular profiling of a malignant tumor? For which of the following tumor types would you be most likely to recommend molecular profiling? Answer these questions and more.


Recent Videos
Based on its mechanism of action, anito-cel may cause fewer instances of cytokine release syndrome and delayed toxicities vs other therapies.
2 experts are featured in this series.
Once a patient-specific dose is determined, an all-oral combination of revumenib plus decitabine/cedazuridine and venetoclax may be “very good” in AML.
Patients with lung cancer who achieve a complete response with neoadjuvant therapy may not experience additional benefit with adjuvant immunotherapy.
Numerous trials have displayed the evolution of EGFR inhibition alone or with chemotherapy/radiation in the EGFR-mutated lung cancer space.
2 experts are featured in this series.
Although high grade adverse effects are infrequent among patients undergoing treatment for SCLC, CRS and ICANS may occur in higher frequencies.
Related Content
The rate of 35% reduction in spleen volume or higher was higher pelabresib/ruxolitinib vs ruxolitinib alone in the MANIFEST-2 trial.

Pelabresib Combo Improves Efficacy Vs Ruxolitinib Alone in Myelofibrosis

Paige Britt
December 9th 2025
Article

The rate of 35% reduction in spleen volume or higher was higher pelabresib/ruxolitinib vs ruxolitinib alone in the MANIFEST-2 trial.

Why Sexual and Gender Minority Care is an Oncologic Imperative

Why Sexual and Gender Minority Care is an Oncologic Imperative

Daniel C. McFarland, DO;Charles S. Kamen, PhD, MPH
December 8th 2025
Podcast

Daniel C. McFarland, DO, and Charles S. Kamen, PhD, MPH, focused on cultural humility, nonverbal data collection, and tailored resources to improve care.

After a median follow-up of 3.9 months, AZD0120 elicited an overall response rate of 96% among 23 patients with relapsed/refractory multiple myeloma.

AZD0120 Displays Early Responses/Manageable Safety in R/R Multiple Myeloma

Silas Inman
December 9th 2025
Article

After a median follow-up of 3.9 months, AZD0120 elicited an overall response rate of 96% among 23 patients with relapsed/refractory multiple myeloma.

Experts highlight considerations for treating patients with oligometastatic kidney cancer, such as differentiating between de novo and recurrent disease.

How to Manage Oligometastatic Kidney Cancer? Insights From IKCS 2025

Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD
December 4th 2025
Podcast

Experts highlight considerations for treating patients with oligometastatic kidney cancer, such as differentiating between de novo and recurrent disease.

The 3-year event-free survival was 88.9% and 30.0% in patients with high-risk LBCL who did and did not achieve a CR at 6 months, respectively.

Axi-Cel Yields Boosted Survival in Patients With High-Risk LBCL and 6-Month CR

Gina Mauro
December 9th 2025
Article

The 3-year event-free survival was 88.9% and 30.0% in patients with high-risk LBCL who did and did not achieve a CR at 6 months, respectively.

Data showed no significant differences in the incidence of CRS and ICANS with the use prophylactic dexamethasone in a retrospective review.

High-Grade ICANS Severity Decreases Via Dexamethasone After Axi-Cel in LBCL

Bridget Hoyt
December 9th 2025
Article

Data showed no significant differences in the incidence of CRS and ICANS with the use prophylactic dexamethasone in a retrospective review.